China Securities Commission Approves Xinbang Asset Reorganization Plan
This article was originally published in PharmAsia News
China’s Securities Regulatory Commission on March 13 approved a major asset reorganization of Xinbang in a transaction totaling RMB 130.7 million ($22.3 million).
You may also be interested in...
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.